VivoSeq
Other

Systemic Therapy

0

Pipeline Programs↗

9

Active Trials↗

2

Companies Involved↗

Systemic Therapy is an early-stage landscape with 0 programs across 2 companies. The most active players are Tempest Therapeutics, Galvanize Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Tempest Therapeutics

0 programs

PreclinicalG

Galvanize Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Completed5 · 29%
Recruiting5 · 29%
Not yet recruiting4 · 24%
Terminated2 · 12%
Unknown status1 · 6%

Clinical Trials

Trial Activity

17 trials

Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs
Recruiting·PPeking University First Hospital·N/A·NCT06652022·102 enrolled
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT06350825·200 enrolled
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Recruiting·FFudan University·Phase 2·NCT06494995·52 enrolled
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
Recruiting·FFirst Hospital of China Medical University·N/A·NCT06632093·84 enrolled
Combination of TURP and Standard Systemic Therapy for MPCa
Recruiting·FFudan University·Phase 2·NCT06655259·200 enrolled
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Not yet recruiting·—·Phase 2·NCT07192848·47 enrolled
Local Injection and Systemic Therapy in the Treatment of NSCLC.
Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT06618391·84 enrolled
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Not yet recruiting·TTempest Therapeutics·Phase 3·NCT06680258·740 enrolled
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06592612·70 enrolled
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Completed·National Cancer Institute (NCI)·Phase 3·NCT00941655·15 enrolled
Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy
Completed·AAbbott·Phase 3·NCT00566722·152 enrolled
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01603212·6 enrolled
A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy
Completed·UUniversity of Pittsburgh·Phase 4·NCT01761019·8 enrolled
A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000673·38 enrolled
Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
Terminated·GGalvanize Therapeutics, Inc.·Phase 4·NCT05583188·5 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)